Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM.
Dou T et al.
Nature Structural & Molecular Biology, 2023
Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale.
Janaszkiewicz A et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2023
Functional Characterization of Rare Variants in OAT1/SLC22A6 and OAT3/SLC22A8 Urate Transporters Identified in a Gout and Hyperuricemia Cohort.
Vávra J et al.
Cells, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2.
Cusato J et al.
Diagnostic Microbiology and Infectious Disease, 2019
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?
Lima A et al.
International Journal of Molecular Sciences, 2015
SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2014
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver.
Shin HJ et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Kiser JJ et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2008
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.
Vormfelde SV et al.
British Journal of Clinical Pharmacology, 2006
Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)].
Xu G et al.
Kidney International, 2005
Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).
Bleasby K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).
Fujita T et al.
Pharmacogenetics and Genomics, 2005